ImpediMed launches share purchase plan as part of A$15.2m capital raise

Impedimed Limited ( (AU:IPD) ) just unveiled an update.

ImpediMed Limited has launched a share purchase plan offering eligible shareholders the chance to acquire up to A$100,000 of new ordinary shares at the lower of A$0.01 per share or a 2.5% discount to the five-day VWAP, targeting proceeds of about A$2.0 million. Participants will also receive one attaching option and one follow-on option per share, and the plan forms part of a broader A$15.2 million capital raising, including a placement whose second tranche and the SPP remain subject to shareholder approval at an extraordinary general meeting on 11 June 2026, with funds earmarked for partial repayment of the SWK facility and additional working capital.

The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.01 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.

More about Impedimed Limited

ImpediMed Limited is an Australian medical technology company listed on the ASX as IPD, focusing on diagnostic and monitoring solutions in the healthcare sector. The company raises capital periodically to support its operations and strengthen its financial position in a competitive medtech market.

YTD Price Performance: -58.82%

Average Trading Volume: 3,556,360

Technical Sentiment Signal: Sell

Current Market Cap: A$17.54M

Learn more about IPD stock on TipRanks’ Stock Analysis page.